JP2016082979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016082979A5 JP2016082979A5 JP2016005407A JP2016005407A JP2016082979A5 JP 2016082979 A5 JP2016082979 A5 JP 2016082979A5 JP 2016005407 A JP2016005407 A JP 2016005407A JP 2016005407 A JP2016005407 A JP 2016005407A JP 2016082979 A5 JP2016082979 A5 JP 2016082979A5
- Authority
- JP
- Japan
- Prior art keywords
- lentiviral
- nucleic acid
- acid sequence
- protein
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 36
- 108090000623 proteins and genes Proteins 0.000 claims 24
- 102000004169 proteins and genes Human genes 0.000 claims 24
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 238000000034 method Methods 0.000 claims 11
- 108020004705 Codon Proteins 0.000 claims 6
- 238000013519 translation Methods 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83049806P | 2006-07-13 | 2006-07-13 | |
| US60/830,498 | 2006-07-13 | ||
| US90661107P | 2007-03-13 | 2007-03-13 | |
| US60/906,611 | 2007-03-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519523A Division JP6199533B2 (ja) | 2006-07-13 | 2007-07-12 | ウイルス阻害性ヌクレオチド配列およびワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016082979A JP2016082979A (ja) | 2016-05-19 |
| JP2016082979A5 true JP2016082979A5 (enExample) | 2016-06-30 |
| JP6415464B2 JP6415464B2 (ja) | 2018-10-31 |
Family
ID=39644991
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519523A Active JP6199533B2 (ja) | 2006-07-13 | 2007-07-12 | ウイルス阻害性ヌクレオチド配列およびワクチン |
| JP2013140710A Active JP6267448B2 (ja) | 2006-07-13 | 2013-07-04 | ウイルス阻害性ヌクレオチド配列およびワクチン |
| JP2016005407A Active JP6415464B2 (ja) | 2006-07-13 | 2016-01-14 | ウイルス阻害性ヌクレオチド配列およびワクチン |
| JP2016197124A Active JP6479739B2 (ja) | 2006-07-13 | 2016-10-05 | ウイルス阻害性ヌクレオチド配列およびワクチン |
| JP2019019455A Pending JP2019107003A (ja) | 2006-07-13 | 2019-02-06 | ウイルス阻害性ヌクレオチド配列およびワクチン |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519523A Active JP6199533B2 (ja) | 2006-07-13 | 2007-07-12 | ウイルス阻害性ヌクレオチド配列およびワクチン |
| JP2013140710A Active JP6267448B2 (ja) | 2006-07-13 | 2013-07-04 | ウイルス阻害性ヌクレオチド配列およびワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016197124A Active JP6479739B2 (ja) | 2006-07-13 | 2016-10-05 | ウイルス阻害性ヌクレオチド配列およびワクチン |
| JP2019019455A Pending JP2019107003A (ja) | 2006-07-13 | 2019-02-06 | ウイルス阻害性ヌクレオチド配列およびワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9422342B2 (enExample) |
| EP (3) | EP2468297B1 (enExample) |
| JP (5) | JP6199533B2 (enExample) |
| AU (1) | AU2007345319B2 (enExample) |
| CA (1) | CA2657626C (enExample) |
| WO (1) | WO2008091283A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008091283A2 (en) * | 2006-07-13 | 2008-07-31 | Institute For Advanced Study | Viral inhibitory nucleotide sequences and vaccines |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| CN107708674A (zh) * | 2015-05-22 | 2018-02-16 | 阿菲欧斯公司 | 联合hiv疗法 |
| WO2021030271A2 (en) | 2019-08-09 | 2021-02-18 | Nutcracker Therapeutics, Inc. | Methods and apparatuses for manufacturing for removing material from a therapeutic composition |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4337028A (en) | 1980-05-27 | 1982-06-29 | The United States Of America As Represented By The United States Environmental Protection Agency | Catalytic monolith, method of its formulation and combustion process using the catalytic monolith |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IL90048A0 (en) | 1988-04-25 | 1989-12-15 | Merck & Co Inc | Recombinant gag precursor of hiv,its preparation and its use as aids vaccine |
| US5639949A (en) | 1990-08-20 | 1997-06-17 | Ciba-Geigy Corporation | Genes for the synthesis of antipathogenic substances |
| US6174666B1 (en) * | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5530195A (en) | 1994-06-10 | 1996-06-25 | Ciba-Geigy Corporation | Bacillus thuringiensis gene encoding a toxin active against insects |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| WO1998022596A1 (en) | 1996-11-19 | 1998-05-28 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | RECOMBINANT VACCINIA VIRUS, PROCESS FOR PREPARING Gag PROTEIN PARTICLE STRUCTURE USING THE SAME, PARTICLE PREPARED BY SAID PROCESS, AND USE THEREOF |
| US6958226B1 (en) | 1998-09-11 | 2005-10-25 | The Children's Medical Center Corp. | Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins |
| EP1980617A1 (en) | 1998-12-31 | 2008-10-15 | Novartis Vaccines and Diagnostics, Inc. | Improved expression of HIV polypeptides and production of virus-like particles |
| EP1200622A4 (en) * | 1999-07-06 | 2004-12-22 | Merck & Co Inc | HIV VACCINE FROM AN ADENOVIRUS CARRYING THE GAG GENE |
| AU779076B2 (en) | 1999-07-28 | 2005-01-06 | Stephen Smith | Conditionally controlled, attenuated HIV vaccine |
| US7879540B1 (en) | 2000-08-24 | 2011-02-01 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
| US20030092145A1 (en) * | 2000-08-24 | 2003-05-15 | Vic Jira | Viral vaccine composition, process, and methods of use |
| CA2424216A1 (en) * | 2000-10-04 | 2002-04-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| EP1572942A2 (en) | 2002-06-27 | 2005-09-14 | The Government of the USA represented by The Department of Health and Human Services Centers for Disease Control & Prevention | Live replicating spumavirus vector |
| JP5145492B2 (ja) | 2002-08-16 | 2013-02-20 | 独立行政法人科学技術振興機構 | 組換えｂｃｇワクチン |
| DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
| US7728118B2 (en) | 2004-09-17 | 2010-06-01 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
| US7861244B2 (en) | 2005-12-15 | 2010-12-28 | International Business Machines Corporation | Remote performance monitor in a virtual data center complex |
| WO2007139584A2 (en) * | 2006-05-25 | 2007-12-06 | Institute For Advanced Study | Methods for identifying sequence motifs, and applications thereof |
| WO2008091283A2 (en) * | 2006-07-13 | 2008-07-31 | Institute For Advanced Study | Viral inhibitory nucleotide sequences and vaccines |
-
2007
- 2007-07-12 WO PCT/US2007/015877 patent/WO2008091283A2/en not_active Ceased
- 2007-07-12 EP EP12160807.9A patent/EP2468297B1/en active Active
- 2007-07-12 AU AU2007345319A patent/AU2007345319B2/en active Active
- 2007-07-12 EP EP12160808.7A patent/EP2468298B1/en active Active
- 2007-07-12 EP EP07872545A patent/EP2041321A4/en not_active Ceased
- 2007-07-12 JP JP2009519523A patent/JP6199533B2/ja active Active
- 2007-07-12 US US12/373,605 patent/US9422342B2/en active Active
- 2007-07-12 CA CA2657626A patent/CA2657626C/en active Active
-
2013
- 2013-07-04 JP JP2013140710A patent/JP6267448B2/ja active Active
-
2016
- 2016-01-14 JP JP2016005407A patent/JP6415464B2/ja active Active
- 2016-08-04 US US15/228,451 patent/US10815277B2/en active Active
- 2016-10-05 JP JP2016197124A patent/JP6479739B2/ja active Active
-
2019
- 2019-02-06 JP JP2019019455A patent/JP2019107003A/ja active Pending